Point : Antihistamines and the Risks They Pose

Canadian Press 1997

Weisnagel J . Antihistamines: An overview of past, present, and future. Modern Medicine of Canada 1990; January:30–40.

Nolen TM . Sedative effects of antihistamines: Safety, performance, learning, and quality of life. Clin Ther 1997; 19:39–45.

Wyngaarden JF Seevers MH . The toxic effects of antihistaminic drugs. JAMA 1951; 145:277–282.

Montella KR . Pulmonary pharmacology in pregnancy. Clin Chest Med 1992; 13:587–595.

Kennard CD . Pharmacologic therapy for urticaria. J Am Acad Dermatol 1991; 25:176–187.

Passalacque G Bousquet J Bachert C . The clinical safety of H1-receptor antagonists. Allergy 1996; 50:666–675.

Lione A Scialli AR . The developmental toxicity of the H1 histamine antagonists. Reprod Toxicol Rev 1996; 4:247–255.

Shenfield G Spry CJF . Unusual cause of agranulocytosis. BMJ 1968; 2:52.

Breathnach S Hinter H , eds. Drugs affecting the immune response. Adverse drug reactions and the skin — 1. Oxford: Blackwell Scientific, 1992:325.

Brandes LJ Warrington O Arron RJ . Enhanced cancer growth in mice administered daily human-equivalent doses of some H1 antihistamines: Predictive in vitro correlates. J Natl Cancer Inst 1994; 86:770–775.

Woosley RL . Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993; 269:1532–1536.

Health Canada Bulletin. Regulatory decision to change terfenadine and astemizole from nonprescription to prescription drug status. 1997; Canadian Drug Directorate publication No. 48.

Monahan BP Ferguson CL Killeavy ES . Torsades de pointes occurring in association with terfenadine use. JAMA 1990; 264:2788–2790.

Nolen TM . Sedative effects of antihistamines: Safety, performance, learning, and quality of life. Clin Ther 1997; 19:39–54.